PSI VisSIG Wonderful Wednesday Webinar Series
This is a good opportunity to develop your knowledge by thinking through a practical example, practicing how to apply graphics principles, and developing your coding skills.
Chrissie Fletcher, PSI Chair
Chrissie is passionate about her profession as a statistician and the significant value statistics has in development and commercialisation of new medicines in the Pharmaceutical Industry.
Chrissie is the VP of Development Biostatistics at GSK and previously held various roles in the Biostatistics at Amgen and SmithKline Beecham.
For nearly 30 years, she has supported a wide range of associations where she is widely recognised for her expertise and leadership in shaping her profession and broader industry initiatives. PSI was the first association Chrissie joined back in 1991 and she has supported ITIT/Training, Scientific, Treasurer and Regulatory activities. Chrissie has also supported a variety of SIG’s, including the HTA SIG, for the last ten years. She was awarded an Honorary Membership in 2019 for her services to PSI.
David Wright, Vice Chair and Secretary
After studying for a MSc in Medical Statistics at the University of Leicester and a PhD in Statistics at QMW, University of London, David did a Post Doc at the University of Warwick on risk scores and became a Lecturer in Medical Statistics at UCL working on risk factors associated with neonatal arterial switch operations.
David has more than 20 years’ experience in the pharmaceutical industry. The first 16 years as a statistical assessor at the MHRA where he went on to Chair the Biostatistics Working Party at the EMA from 2011-2016. Since 2016 David has worked for AstraZeneca as Head of Statistical Innovation leading a team working on methodological issues associated with the design and analysis of clinical trials.
David co-authored the revision to the CHMP guideline on missing data and is a member of the EFPSI/EFPIA Estimands Implementation Working Group and a member of the EFSPI Scientific Committee.
Kimberley Hacquoil, Careers Director
Kim has over 15 years’ of experience in the pharmaceutical industry working as a statistician. She has worked in a number of different therapeutic areas, mainly in early development. She has championed new approaches to decision making in clinical development through initiatives developing and promoting innovative/novel designs, and statistical methodology including futility and predictive inference, prior elicitation, assurance and quantitative decision making. She has also worked in strategy and portfolio management as a Statistics & Mathematical Modelling Director. Kim has recently taken on a new role as the Chief Data Scientific Officer at Exploristics.
Kim has been an active member of PSI for many years and has previously been part of the New Starters SIG and the Careers and Academic Liaison Committee (CALC).
Kim received her BSc in Mathematics from Bath University and MPhil in Statistical Sciences from Cambridge University.
Aiden Flynn, Commercial Director
Dr Aiden Flynn has over 25 years’ experience in drug discovery and clinical development, with ten years at GlaxoSmithKline as a Director of Statistical Support for Biomarker Studies across R&D. There he was responsible for developing and implementing the company’s Pharmacogenetics strategy enabling the use of genetics data in clinical studies. This involved the development and integration of new analysis tools and methods, data standards, processes and training. Aiden has in-depth experience in developing computer simulation tools for the design and analysis of complex trials and has worked closely with the FDA and EMA to develop tools and guidelines that support the use of biomarkers in clinical studies.
In 2009, he set up Exploristics, a privately owned, commercial company providing statistical products and services in support of clinical trial design and analysis. Since it was founded, Aiden has overseen the consistent growth in the company.
Alun Bedding, Communications Committee and External Affairs (and EFSPI) Chair
Alun is the current Global Head of Methods, Collaboration and Outreach in the Statistics department at Roche. He has worked in the pharmaceutical industry for over 30 years and been a member of PSI for all that time having also served on the Board of Directors twice previously, first as Secretary and latterly as Treasurer. Alun also worked as editor on the SPIN newsletter in the past. Alun is currently involved with the PSI mentor program and has been the internal auditor for PSI.
Alun is a member of the DIA Innovative Design Working Group and Bayesian Methods Working Group and also a statistical member of the UK Medical Research Council Experimental Medicine funding panel and the Great Ormond Street Hospital funding panel.
Rachael Lawrance, Events Director
Rachael is a Principal Statistician at Adelphi Values Patient Centered Outcomes team, focused on the analysis and interpretation of PRO data, particularly in the context of clinical trials (3-days a week). She also occasionally works part-time as a freelance statistical consultant, with a focus on statistical work for small healthcare companies. Rachael previously worked at AstraZeneca for sixteen years; most recently as a lead project statistician in oncology projects, including those with companion-diagnostics. Rachael has a slightly unusual career route to becoming a statistician in the pharmaceutical industry, as she has a BSc Biochemistry and Genetics - she started at AZ as a molecular geneticist -- but has gradually been drawn into the world of statistics and enjoys the application of statistics in practice.
After leaving AZ Rachael was keen to stay connected to Pharma Statisticians and therefore joined the PSI Scientific Committee member in 2016. Rachael enjoys organising events and has been co-organising one-day meetings, webinars & PSI conferences and joined the PSI Board as scientific chair in June 2019.
Rachael loves the outdoors and is a keen fell runner and is also slightly infamous for completing long races (marathon distance and beyond). She has two boys who are currently at primary school so family life keeps her busy too!
Connect via LinkedIn:
Kate Tsirtsonis, Membership Chair
Kate has over 15 years of experience in the Pharmaceutical Industry, working as a Statistician and a Statistical Programmer across early and late stage therapeutic areas, performing varying roles. She is currently European Statistical Lead for General Medicine within Amgen.
Before joining the Pharmaceutical Industry, Kate obtained a Bsc in Maths with Actuarial Studies and an Msc in Medical Statistics from the University of Southampton.
Kate has been involved in PSI for many years but is now enjoying taking an active part in the PSI Membership Committee, focusing on widening out the PSI community.
Outside of work, Kate is a keen, yet distinctly average, runner. She also has two active young boys, so family life keeps her very busy.
Adam Crisp, Special Interest Group (SIG) Director
Adam is Head of Infectious Disease Statistics at GSK with 25 years’ industry experience across all phases of drug development and multiple therapeutic areas. Educated and based in the UK, Adam has extensive experience in the design and conduct of cardiovascular outcomes trials and in working with the associated external groups. Adam is a member of GSK’s “Global Safety Board” and is a GSK Senior Fellow. Adam has previously served on the PSI Scientific Committee and joined the Board in December 2019.
Adam has a range of statistical interests, with recent publications on topics such as use of assurance to support decision making in drug development, the changing landscape of Data Monitoring Committees and a wide-ranging overview of blinding in clinical trials; recent external presentations have included contributions as a keynote speaker at the Indian Association for Statisticians in Clinical Trials 2018 conference (on Go/No-go criteria), as panellist at the 2017 ISBS Conference session “Data Monitoring Committees – Scope, Expectations and Challenges” and as speaker at the 2016 ASA Biopharmaceutical Workshop on “Futility assessments in late-phase drug development: a novel two-stage outcomes trial in Acute Coronary Syndrome”.
Adam received his PhD in Statistics from University College London and has a Diploma in Mathematical Statistics from Cambridge University.
Markus Elze, Contracts and Finance Director
Markus Elze is Biostatistician at Roche with a focus on late stage Oncology, based in Basel. He works mainly in cancer immunotherapy, including some early phase and paediatric trials, as well as in biomarker work. His interests include computational tools (especially R for the generation of valid outputs), decision-making in early phase settings and paediatric studies.
Markus has been an active member of PSI for several years, including presentations at the conference and membership in the PSI AIMS SIG. He is an active member of RSS and was also a Young Statisticians Section Committee member in 2016.
Markus obtained his PhD in Statistics from the University of Warwick with a thesis on joint modelling of time-to-event and longitudinal processes and did a PostDoc at The London School of Tropical Medicine.
Markus’ hobbies include technology, space, travelling and food.